Only two cohort studies have reported ORR in newly diagnosed IDH-mutated AML patients receiving IDH inhibitor monotherapy, and we hypothesize that different IDH inhibitors are a major source of heterogeneity. The gene discussed is IDH2; the disease is acute myeloid leukemia.